NASDAQ · Health Care

MEDPACE HLDGS INC MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

Biotechnology: Commercial Physical & Biological Resarch

Company profile

Business mix

  • The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
  • It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries.
  • In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
  • Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within diagnostics & research?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 4 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 28.57 FCF 5.48% Buyback 8.94%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.2% $241.6M 2026-03-31
Giverny Capital Francois Rochon 4.5% $123.0M 2026-03-31
Vulcan Value Partners C.T. Fitzpatrick 2.6% $97.5M 2026-03-31
Fundsmith Terry Smith 0.2% $30.1M 2026-03-31

Recent trading changes over the last 1 quarters

Net buyers 1 Last 1 13F filing periods
Net reducers 3 Last 1 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $74.8M Estimated from net added shares
Reduction amount $34.1M Estimated from net reduced shares
Net share change / base shares +9.0% +84,737 / 940,271
Fundsmith Terry Smith 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -24.1% 13F value change -$16.3M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 82,567 Last 1 periods -19,899 (-24.1%) Total shares 62,668 Value $30.1M
Giverny Capital Francois Rochon 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -2.7% 13F value change -$24.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 263,320 Last 1 periods -7,239 (-2.7%) Total shares 256,081 Value $123.0M
Vulcan Value Partners C.T. Fitzpatrick 1 filing periods
13F 2026-03-31 Filed 2026-05-11
Major increase Shares 329.3% 13F value change +$70.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-11
Base shares 47,306 Last 1 periods +155,762 (+329.3%) Total shares 203,068 Value $97.5M
Baillie Gifford legacy James Anderson 1 filing periods
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -8.0% 13F value change -$65.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 547,078 Last 1 periods -43,887 (-8.0%) Total shares 503,191 Value $241.6M

Recent mentions

No public mentions.